4basebio (LON:4BB) Posts Earnings Results

4basebio (LON:4BB) released its quarterly earnings data on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

4basebio Trading Down 0.5%

LON 4BB traded down GBX 2.70 during mid-day trading on Wednesday, reaching GBX 559.80. 115 shares of the stock were exchanged, compared to its average volume of 1,346. The stock has a 50 day simple moving average of GBX 512.25 and a 200-day simple moving average of GBX 510.12. 4basebio has a one year low of GBX 420 and a one year high of GBX 820. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The stock has a market cap of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reduced their target price on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research note on Monday, June 15th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of GBX 1,400.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.